Literature DB >> 14586894

Host and donor risk factors before and after liver transplantation that impact HCV recurrence.

Marina Berenguer1.   

Abstract

1. The natural history of hepatitis C after liver transplantation is variable. Several factors, including those related to the virus, the host, the environment and the donor, are probably implicated in the outcome. 2. The immune status per se likely represents the main significant variable in influencing disease severity in hepatitis C virus-infected patients. Findings that support this statement include the higher aggressivity of hepatitis C in immunocompromised liver transplant recipients as compared with that observed in immunocompetent patients, both before and after the development of compensated cirrhosis, and the significant association described between the degree of immunosuppression and disease severity. 3. Similar to that observed in the immunocompetent population, the age at the time of infection (age of the donor) strongly affects posttransplantation hepatitis C virus-related disease progression. 4. Hepatitis C-related disease progression is faster in patients who underwent transplantation in recent years as compared with those who underwent transplantation in earlier cohorts. The increasing age of the donor and the use of stronger immunosuppression may, in part, explain the worse outcomes seen in recent years. 5. Additional host-related variables predictive of outcome include the immunogenetic background, the timing of recurrence, and the early histologic findings.

Entities:  

Mesh:

Year:  2003        PMID: 14586894     DOI: 10.1053/jlts.2003.50243

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  13 in total

Review 1.  Liver transplantation organ allocation between Child and MELD.

Authors:  Ivo Graziadei
Journal:  Wien Med Wochenschr       Date:  2006-07

2.  Antithymocyte globulin induction therapy in hepatitis C-positive liver transplant recipients.

Authors:  Peter J Horton; Jean Tchervenkov; Jeff S Barkun; Caroline Rochon; Prosanto K Chaudhury; Tammy L Znajda; John B Martinie; Peter Metrakos
Journal:  J Gastrointest Surg       Date:  2005 Sep-Oct       Impact factor: 3.452

3.  HCV in liver transplantation.

Authors:  Giacomo Germani; Emmanuel Tsochatzis; Vasilios Papastergiou; Andrew K Burroughs
Journal:  Semin Immunopathol       Date:  2012-07-25       Impact factor: 9.623

4.  Association of genetic variants with rapid fibrosis: progression after liver transplantation for hepatitis C.

Authors:  Jennifer E Layden; Bamidele O Tayo; Scott J Cotler; Nina M Clark; Kristine Baraoidan; Scott L Friedman; Richard S Cooper
Journal:  Transplantation       Date:  2014-05-27       Impact factor: 4.939

5.  Management practices of hepatitis C virus infected alcoholic hepatitis patients: A survey of physicians.

Authors:  Ashwani K Singal; Habeeb Salameh; Anjna Singal; Sarat C Jampana; Daniel H Freeman; Karl E Anderson; Don Brunder
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-05-06

Review 6.  Management of post transplant hepatitis C in the direct antiviral agents era.

Authors:  Audrey Coilly; Bruno Roche; Jean-Charles Duclos-Vallée; Didier Samuel
Journal:  Hepatol Int       Date:  2015-03-28       Impact factor: 6.047

Review 7.  Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review.

Authors:  Oscar Mitchell; Ahmet Gurakar
Journal:  J Clin Transl Hepatol       Date:  2015-06-15

Review 8.  Hepatitis C Recurrence after Orthotopic Liver Transplantation: Mechanisms and Management.

Authors:  Bobby Kakati; Anil Seetharam
Journal:  J Clin Transl Hepatol       Date:  2014-09-15

9.  Antihepatitis C virus therapy in liver transplanted patients.

Authors:  Antonino Picciotto
Journal:  Ther Clin Risk Manag       Date:  2006-03       Impact factor: 2.423

Review 10.  Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance.

Authors:  Bruno Roche; Audrey Coilly; Anne-Marie Roque-Afonso; Didier Samuel
Journal:  Viruses       Date:  2015-09-23       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.